Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe

被引：0

作者：

David R. Coghill

Tobias Banaschewski

Peter Nagy

Isabel Hernández Otero

César Soutullo

Brian Yan

Beatriz Caballero

Alessandro Zuddas

机构：

[1] University of Melbourne,Departments of Paediatrics and Psychiatry, Faculty of Medicine, Dentistry and Health Sciences

[2] University of Dundee,Central Institute of Mental Health

[3] Medical Faculty Mannheim,Child and Adolescent Neuropsychiatry Unit, Department of Biomedical Sciences

[4] University of Heidelberg,undefined

[5] Vadaskert Child and Adolescent Psychiatry Hospital and Outpatient Clinic,undefined

[6] University Hospital Virgen de la Victoria,undefined

[7] University of Navarra Clinic,undefined

[8] Shire,undefined

[9] Shire,undefined

[10] University of Cagliari,undefined

来源：

CNS Drugs | 2017年 / 31卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：625 / 638

页数：13

共 50 条

[31] Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
Kudrow, David
Cady, Roger K.
Allan, Brent
Pederson, Susan M.
Hirman, Joe
Mehta, Lahar R.
Schaeffler, Barbara A.
BMC NEUROLOGY, 2021, 21 (01)
[32] Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
David Kudrow
Roger K. Cady
Brent Allan
Susan M. Pederson
Joe Hirman
Lahar R. Mehta
Barbara A. Schaeffler
BMC Neurology, 21
[33] An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan
Ichikawa, Hironobu
Hiratani, Michio
Yasuhara, Akihiro
Tsujii, Noa
Oshimo, Takashi
Ono, Hiroaki
Tadori, Yoshihiro
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (02) : 84 - 94
[34] An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia
Gahan Pandina
Stuart Kushner
Keith Karcher
Magali Haas
Child and Adolescent Psychiatry and Mental Health, 6 (1)
[35] Safety and effectiveness of long-term treatment with lurasidone in children and adolescents with bipolar depression: A 6-month interim analysis of a 2-year open-label extension study
Chang, K.
Tocco, M.
Goldman, R.
Pikalov, A.
Deng, L.
Cucchiaro, J.
Loebel, A.
EUROPEAN PSYCHIATRY, 2018, 48 : S81 - S82
[36] Effectiveness of long-term treatment with lurasidone in children and adolescents with bipolar depression: week 28 results of a 2-year open-label extension study
Chang, K.
DelBello, M.
Goldman, R.
Tocco, M.
Pikalov, A.
Deng, L.
Cucchiaro, J.
Loebel, A.
BIPOLAR DISORDERS, 2018, 20 : 65 - 65
[37] Participant-Perceived Quality of Life in a Long-Term, Open-Label Trial of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder
Childress, Ann C.
Cutler, Andrew J.
Saylor, Keith
Gasior, Maria
Hamdani, Mohamed
Ferreira-Cornwell, M. Celeste
Findling, Robert L.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2014, 24 (04) : 210 - 217
[38] EFFICACY OF LONG-TERM TREATMENT WITH VILOXAZINE EXTENDED-RELEASE CAPSULES (QELBREE™) IN CHILDREN AND ADOLESCENTS WITH ADHD: AN OPEN-LABEL EXTENSION STUDY
Nasser, Azmi
Hull, Joseph
Chaturvedi, Soumya
Maldonado-Cruz, Zulane
Liranso, Tesfaye
Qin, Peibing
Busse, Gregory
Rubin, Jonathan
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 60 (10): : S258 - S258
[39] COGNITIVE FUNCTION IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER RECEIVING LISDEXAMFETAMINE DIMESYLATE IN A 2-YEAR SAFETY STUDY
Coghill, D.
Banaschewski, T.
Bliss, C.
Robertson, B.
Zuddas, A.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2017, 51 : 106 - 107
[40] Long-term Safety and Efficacy of Etanercept in Patients With Psoriasis: An Open-label Study
Leonardi, Craig
Strober, Bruce
Gottlieb, Alice B.
Elewski, Boni E.
Ortonne, Jean-Paul
van de Kerkhof, Peter
Chiou, Chiun-Fang
Dunn, Meleana
Jahreis, Angelika
JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (08) : 928 - 937

← 1 2 3 4 5 →